References
- Jacobsson L. T., Lindroth Y., Marsal L., Juran E., Bergstrom U., Kobelt G. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community‐derived population in Malmö, Sweden. Scand J Rheumatol 2007; 36: 179–83
- Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 2006; 35: 415–25
- Mancuso C. A., Paget S. A., Charlson M. E. Adaptations made by rheumatoid arthritis patients to continue working: a pilot study of workplace challenges and successful adaptations. Arthritis Care Res 2000; 13: 89–99
- Katz P. P. The impact of rheumatoid arthritis on life activities. Arthritis Care Res 1995; 8: 272–8
- Van Veldhoven M. J. P. M., Meijman T. F. [Questionnaire on psychosocial job demands and job stress], in Dutch. NIA, Amsterdam 1994
- Balder B., Lindholm N. B., Lowhagen O., Palmqvist M., Plaschke P., Tunsater A., et al. Predictors of self‐assessed work ability among subjects with recent‐onset asthma. Respir Med 1998; 92: 729–34
- De Jong Z., van der Heijde D., McKenna S. P., Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis‐specific quality of life instrument. Br J Rheumatol 1997; 36: 878–83
- Beurskens A. J., Bultmann U., Kant I., Vercoulen J. H., Bleijenberg G., Swaen G. M. Fatigue among working people: validity of a questionnaire measure. Occup Environ Med 2000; 57: 353–7
- van Veldhoven V. M., Broersen S. Measurement quality and validity of the ‘need for recovery scale’. Occup Environ Med 2003; 60((Suppl 1))i3–9
- Drummond M. F., Sculpher M. J., Torrance G. W., O'Brien B. J., Stoddart G. L. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford 2005
- Mushkin S. J. Health as an investment. J Polit Econ 1962; 70: 129–57
- Navarro‐Sarabia F., Ariza‐Ariza R., Hernandez‐Cruz B., Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005; 3: CD005113
- Moreland L. W., Genovese M. C., Sato R., Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum 2006; 55: 287–93
- Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A., et al. Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35–45
- Smolen J. S., Han C., van der Heijde D., Emery P., Bathon J. M., Keystone E., et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006; 54: 716–22